United States Patent and Trademark Office
Home
|
Site Index
|
Search
|
Guides
|
Contacts
|
e
Business
|
eBiz alerts
|
News
|
Help
TTABVUE. Trademark Trial and Appeal Board Inquiry System
v2.3.0
Opposition
Number:
91218183
Filing Date:
09/02/2014
Status:
Terminated
Status Date:
01/14/2015
General Contact Number:
571-272-8500
Interlocutory Attorney:
CHRISTEN M ENGLISH
Paralegal Name:
NICOLE M THIER
Defendant
Name:
Actavis Group PTC ehf
Correspondence:
GABRIELLE S ROTH
SUGHRUE MION PLLC
2100 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20037-3213
UNITED STATES
groth@sughrue.com, tm@sughrue.com, kdunmire@sughrue.com, mwhite@sughrue.com
Phone: 202-293-7060
Serial #:
79130027
Application File
Assignment
Registration #:
4686257
Application Status:
CANCELLED - SECTION 71
Mark:
ACTAVIS LABORATORIES
Plaintiff
Name:
Genentech, Inc.
Correspondence:
HAROLD J MILSTEIN
SHEPPARD MULLIN RICHTER & HAMPTON LLP
379 LYTTON AVENUE
PALO ALTO, CA 94301
UNITED STATES
svtmdocketing@sheppardmullin.com, hmilstein@sheppardmullin.com, cbush@sheppardmullin.com
Phone: 650-815-2600
Serial #:
73534873
Application File
Assignment
Registration #:
1398216
Application Status:
REGISTERED AND RENEWED
Mark:
ACTIVASE
Serial #:
78546712
Application File
Assignment
Registration #:
3613829
Application Status:
Cancelled - Section 8
Mark:
ACTIVASE ALTEPLASE A RECOMBINANT TISSUEPLASMINOGEN ACTIVATOR THE ONE T-PA FOR STROKE
Serial #:
78546717
Application File
Assignment
Registration #:
3584619
Application Status:
Cancelled - Section 8
Mark:
CATHFLO ACTIVASE (ALTEPLASE) THE ONE 2-MG T-PA
Prosecution History
#
Date
History Text
Due Date
9
01/14/2015
TERMINATED
8
01/14/2015
BD DECISION: DISMISSED W/O PREJ
7
12/11/2014
MOT TO AMEND APPLICATION
6
11/06/2014
EXTENSION OF TIME GRANTED
5
11/06/2014
D MOT FOR EXT W/ CONSENT
4
09/29/2014
TRIAL DATES RESET
3
09/04/2014
PENDING, INSTITUTED
2
09/04/2014
NOTICE AND TRIAL DATES SENT; ANSWER DUE:
10/14/2014
1
09/02/2014
FILED AND FEE
Results as of 01/30/2023 07:37 AM
Search:
|
.
HOME
|
INDEX
|
SEARCH
|
e
BUSINESS
|
CONTACT US
|
PRIVACY POLICY